Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
NASDAQ
$10.91
▼ DOWN 1.98% (-0.22)

KEY STATISTICS

Market Cap$202.14 M
52w High$20.56
52w Low$7.12
Dividend Yield—
Frequency—
P/E-1.76
Volume583.25K
Shares Out.18.53M

COMPANY

LEADERSHIP

Yuval Cohen
CHIEF EXECUTIVE
Yuval Cohen

COMPENSATION 2026

Salary$646,566
Stock Awards$666,699
Incentive Plan Pay$0
All Other Comp.$23,884
Total$3,750,125

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 27, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
36

PRICE TARGET

Target High$35.00
Target Low$33.00
Target Median$33.00
Target Consensus$33.67

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$1.67M
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2023-02-14Reverse1:30

PRICE

$10.91 ▼ DOWN 1.98% (−$0.22)
OVERLAYS
$10.80$10.95$11.10$11.259:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM10.91

About Corbus Pharmaceuticals Holdings, Inc.

https://www.corbuspharma.com ↗

Corbus Pharmaceuticals develops immune modulators targeting immuno-oncology and fibrosis, including lenabasum and monoclonal antibodies, for diseases like lupus, cancer, fibrosis, and metabolic disorders.

INDUSTRY

Biotechnology

A PRODUCT CORBUS PHARMACEUTICALS HOLDINGS, INC. IS KNOWN FOR

CRB-701
CRB-701

CRB-701 is a next-generation ADC targeting Nectin-4 in solid tumors, with FDA Fast Track designations for head and neck squamous cell carcinoma and cervical cancer, exemplifying Corbus's focus on precision oncology.

COMPETITORS

COMPETITOR
ABBV COMPARE
BCYC COMPARE
GILD COMPARE
IPHA COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
50
LISTED HERE
9
RANKED BY POSITION SIZE
VTI
0.00% · 533.6K
XSU.TO
0.01% · 401.6K
FESM
0.01% · 87.1K
DFAS
0.00% · 58.4K
AVSC
0.01% · 26.5K
XRS2.DE
0.01% · 15.4K
RSSL
0.01% · 7.8K
URTY
0.00% · 669
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
5.70%
HOLDERS
20
TOP 12 OF 20 · RANKED BY POSITION SIZE
Blackrock Institutional Trust Company, N.A.
545.4K sh · $4.61M
Teachers Advisors, LLC
104.5K sh · $727K
Everpoint Asset Management, LLC
102.6K sh · $867K
Blackrock Fund Advisors
102.5K sh · $867K
Tiaa Cref Investment Management LLC
99.5K sh · $692K
Kingsbury Capital Investment Advisors LLC
33.7K sh · $6K
Jump Trading, LLC
28.1K sh · $195K
Yellowstone Partners, LLC
15.3K sh · $109K
Advisor Group, Inc.
6.9K sh · $38K
Blackrock Investment Management, LLC
6.6K sh · $56K
Blackrock Advisors LLC
6.2K sh · $52K
Bb&T Investment Services, Inc.
4.5K sh · $32K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Nicacio Leonardo Viana
Purchase · 191.7K shares
2026-08-16
★
OFFICER: CHIEF MEDICAL OFFICER
Nicacio Leonardo Viana
Purchase · 58.3K shares
2026-08-16
★
OFFICER: CHIEF BUSINESS OFFICER
Saxena Nishant C
Purchase · 2.6K shares
2026-08-11
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Cohen Yuval
Sale · 17.0K shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 4
BUY 3
7 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM HC Wainwright & Co. BUY Mizuho OUTPERFORM Wedbush OUTPERFORM Guggenheim BUY Jefferies BUY RBC Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
FBRX$76.99COMPARE
ALEC$2.34COMPARE
PEPG$3.08COMPARE
IPHA$2.22COMPARE
MOLN$4.50COMPARE
MIST$1.16COMPARE
CRDF$0.94COMPARE
RANI$0.84COMPARE